Genoway SA
PAR:ALGEN

Watchlist Manager
Genoway SA Logo
Genoway SA
PAR:ALGEN
Watchlist
Price: 2.38 EUR -3.25% Market Closed
Market Cap: 22.6m EUR

EV/EBITDA
Enterprise Value to EBITDA

3.2
Current
5.8
Median
6.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
3.2
=
Enterprise Value
19.9m EUR
/
EBITDA
6.1m EUR
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
FR
Genoway SA
PAR:ALGEN
Average EV/EBITDA: 35.2
3.2
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.4
839%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
6.4
2-Years Forward
EV/EBITDA
5.4
3-Years Forward
EV/EBITDA
4